HAYWARD, Calif.--(EON: Enhanced Online News)--Moximed®, Inc., a medical device company pioneering the development of joint unloading treatments for patients with early osteoarthritis (OA), announced today that the 500th worldwide implant of its KineSpring® System was successfully completed. The KineSpring System is an implantable medical spring that works by unloading the weight on the diseased knee joint, without changes to the anatomy. Since the first KineSpring Procedure over five years ago, continued positive patient outcomes and a streamlined surgical technique have resulted in accelerated surgeon adoption for patients with knee OA.
“The KineSpring System offers a joint-preserving surgical alternative for my younger, more active patients with medial knee OA. Five years after implanting the first ever KineSpring System, I remain enthusiastic about the potential of the KineSpring System as an effective treatment option for this difficult patient group.”
A distinct treatment gap exists for patients with symptomatic medial knee OA. Many patients are dissatisfied with conservative care but hope to avoid or delay knee replacement.1 Arthritis is the leading cause of disability, and over 15 million people in the US suffer from knee OA.2 The costs associated with arthritis and joint pain in the US are estimated at nearly $300 billion annually.3
The 500th KineSpring System implant was performed by Jack Farr, M.D., Director of the OrthoIndy Cartilage Restoration Center of Indiana and the OrthoIndy Sports Medicine Fellowship Program. Dr. Farr, who is the Lead Principal Investigator of the US-based SOAR clinical study of the KineSpring System commented, “I continue to be impressed by the potential of the unloading concept as a treatment option for patients with knee OA. My experience has validated significant patient interest in the KineSpring System, and I am encouraged by positive outcomes that have been generated by pioneering surgeons in Australia and Europe.”
David Hayes, M.D., of the Brisbane Orthopaedic and Sports Medicine Centre (Australia), who implanted the first KineSpring System in 2008 stated, “The KineSpring System offers a joint-preserving surgical alternative for my younger, more active patients with medial knee OA. Five years after implanting the first ever KineSpring System, I remain enthusiastic about the potential of the KineSpring System as an effective treatment option for this difficult patient group.”
“The continued and growing acceptance of the KineSpring System, as evidenced by the achievement of this significant milestone, is very encouraging. It is clear that both surgeons and patients worldwide value the clinical and economic benefits shown by the KineSpring System. Above all, we are most proud to have played a part in the return of a significant number of patients to an active, high-quality lifestyle,” said Kevin Sidow, President and CEO of Moximed.
Osteoarthritis (OA), the most common form of arthritis, is a degenerative disease affecting the hands, knees, hips, feet and spine. According to the Centers for Disease Control and Prevention (CDC), OA affects 27 million adults in the US (15 million Americans specifically have knee OA). It is caused by changes in cartilage, the soft tissue that cushions and protects bone, leading to pain and changes in the shape of the joint. In knee OA, as the cartilage wears away, the bone ends may begin to rub against each other, causing severe pain. While drugs and certain cartilage repair procedures may temporarily relieve pain, they often do not treat the underlying problems that led to OA. Conversely, research suggests that if the excess stress on the joint is removed, as with the KineSpring System, pain may decrease and the natural joint tissues may demonstrate some recovery.
About the KineSpring System
The KineSpring System is intended to provide an innovative treatment option for patients with mild-to-moderate knee osteoarthritis who find conservative therapy, such as pain medication and knee braces, unsuccessful, but who are not ready for joint-altering knee surgery. The KineSpring System is implanted in the subcutaneous tissue alongside the joint to cushion the knee from excessive loading. Importantly, the KineSpring System is completely joint-sparing, so future treatment options are maintained.
The KineSpring System is CE marked in Europe and has been successfully implanted into 500 osteoarthritis patients. It is investigational in the US and only available in the US as part of the FDA approved SOAR clinical study.
Moximed Inc is dedicated to improving the standard of care for patients with osteoarthritis. OA, the most common form of arthritis, leads to a breakdown of the joint’s cartilage and often results in joint pain and loss of motion. OA commonly affects the knees, hips, hands, or back. Moximed is initially focused on developing minimally invasive, joint preserving solutions for patients with knee osteoarthritis. Moximed is supported by world-leading venture investors including New Enterprise Associates (NEA), Morgenthaler Ventures, Frazier Healthcare Ventures, Gilde Healthcare Partners, GBS Venture Partners. More information can be found at www.moximed.com.
1 London NJ et al. Clinical and economic consequences of the treatment gap in knee osteoarthritis Management. Medical Hypotheses 2011; 76: 887-892.
2 MAKO Surgical Investor Presentation, Jan 2013. Downloaded October 8, 2013 from http://files.shareholder.com/downloads/MAKO/2454715907x0x627601/d383e106-e885-465d-b200-ce56a559b746/MAKO%20Company%20Presentation%2001072013%20(2).pdf.
3 Orthopaedic Industry Annual Report. Orthoworld 2012.